타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | 1L–2L after metformin (T2D); chronic weight management |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus) |
Positioning Known limitation | GI intolerance leading to discontinuation; plateau after dose titration |
Positioning Development positioning | 1L–2L after metformin (T2D); chronic weight management |
MoA Mechanism | Semaglutide activates GLP-1 receptors on pancreatic beta cells (glucose-dependent insulin secretion), suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. |
MoA Biomarker | HbA1c, body weight, SELECT CV outcomes in obesity with CVD. |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Safety signal | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교